Trial Profile
A Multi-Centre Randomised, Double-Blind, Double-Dummy Parallel Group Study of the Onset and Offset of Antiplatelet Effects of AZD6140 Compared With Clopidogrel and Placebo With Aspirin as Background Therapy in Patients With Stable Coronary Artery Disease (CAD).
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary) ; Clopidogrel
- Indications Arterial thrombosis
- Focus Therapeutic Use
- Acronyms ONSET-OFFSET
- Sponsors AstraZeneca
- 10 Nov 2018 Results characterizing ticagrelor exposure-response relationship for platelet inhibition in patients with stable coronary artery disease (CAD) and a history of myocardial infarction (MI), using non-linear mixed effects modelling and simulation of two trials (NCT00528411 and NCT01225562) published in the British Journal of Clinical Pharmacology
- 30 Aug 2010 Results have been presented at ESC Congress 2010: Annual Congress of the European Society of Cardiology.
- 18 Nov 2009 Results on the effects on cardiopulmonary function have been presented at the American Heart Association Scientific Sessions.